Transmedics Group Inc [TMDX] stock prices are down -0.59% to $165.00 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The TMDX shares have gain 8.97% over the last week, with a monthly amount drifted -4.60%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Transmedics Group Inc [NASDAQ: TMDX] stock has seen the most recent analyst activity on August 21, 2024, when Needham initiated its Buy rating and assigned the stock a price target of $208. Previously, Cantor Fitzgerald started tracking the stock with Overweight rating on June 06, 2024, and set its price target to $161. On June 04, 2024, Stephens initiated with a Overweight rating and assigned a price target of $151 on the stock. Piper Sandler started tracking the stock assigning a Overweight rating and suggested a price target of $95 on March 28, 2024. Robert W. Baird initiated its recommendation with a Outperform. JP Morgan upgraded its rating to Overweight for this stock on August 02, 2022, but kept the price target unchanged to $48. In a note dated October 08, 2020, JP Morgan downgraded an Neutral rating on this stock but restated the target price of $15.
The stock price of Transmedics Group Inc [TMDX] has been fluctuating between $36.42 and $177.37 over the past year. Currently, Wall Street analysts expect the stock to reach $156.86 within the next 12 months. Transmedics Group Inc [NASDAQ: TMDX] shares were valued at $165.00 at the most recent close of the market. An investor can expect a potential drop of -4.93% based on the average TMDX price forecast.
Analyzing the TMDX fundamentals
The Transmedics Group Inc [NASDAQ:TMDX] reported sales of 358.76M for trailing twelve months, representing a surge of 117.87%. Gross Profit Margin for this corporation currently stands at 0.61% with Operating Profit Margin at -0.0%, Pretax Profit Margin comes in at 0.0%, and Net Profit Margin reading is 0.01%. To continue investigating profitability, this company’s Return on Assets is posted at 0.0, Equity is 0.02 and Total Capital is -0.0. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of2.69.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 161.48 points at the first support level, and at 157.97 for the second support level. However, for the 1st resistance point, the stock is sitting at 168.90, and for the 2nd resistance point, it is at 172.81.
Ratios To Look Out For
It’s worth pointing out that Transmedics Group Inc [NASDAQ:TMDX]’s Current Ratio is 9.37. As well, the Quick Ratio is 8.48, while the Cash Ratio is 6.68. Considering the valuation of this stock, the price to sales ratio is 15.34, the price to book ratio is 28.95 and price to earnings (TTM) ratio is 4621.85.
Transactions by insiders
Recent insider trading involved Hassanein Waleed H, President & CEO, that happened on Sep 16 ’24 when 8625.0 shares were sold. Chief Commercial Officer, Khayal Tamer I completed a deal on Sep 03 ’24 to sell 2960.0 shares. Meanwhile, Corcoran Nicholas sold 10000.0 shares on Aug 27 ’24.
